A phase 2 dose de-escalation trial based on PET/CT early response assessment in childhood and adolescent nasopharyngeal carcinoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047434

Enrollment

Unknown

Registered

2021-06-18

Start date

2021-06-17

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

Experimental group:de-escalated radiotherapy

Eligibility

Sex/Gender

All

Age

8 Years to 21 Years

Inclusion criteria

Inclusion criteria: 1.Aged 8 to 21 years; 2.ECOG Performance Status 0-1; 3.Pathologically confirmed EBER positive nasopharyngeal carcinoma; 4.No distant metastasis in staging examination.

Exclusion criteria

Exclusion criteria: 1.Patients can not tolerate staging examination and radiotherapy; 2.Hepatic and renal insufficiency; 3.Other serious medical complications; 4.The attending doctor believes that there are other unsuitable conditions for enrollment.

Design outcomes

Primary

Measure	Time frame
3-year progression-free survival rate;	—

Countries

China

Contacts

Public ContactWu Runye

Cancer Hospital, Chinese Academy of Medical Sciences

wurunye@126.com+86 13522457547

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026